Article
EGFR mutation prevalence, real-world treatment patterns, and outcomes among patients with resected, early-stage, non-small cell lung cancer in Canada.
Lung cancer (Amsterdam, Netherlands) - 1 Nov 2022
Sara Kuruvilla M, Liu Geoffrey, Syed Iqra, Gwadry-Sridhar Femida, Sheffield Brandon S, Sachdeva Robin, Pencz Alec, Zhan Luna, Hueniken Katrina, Patel Devalben, Balaratnam Karmugi, Khan Khaleeq, Grant Benjamin, Noy Shawna, Singh Karan, Liu Linda, Rakibuz-Zaman Muhammad, Moldaver Daniel, Kate Shanahan Mary, Cheema Parneet K
Abstract excerpt
OBJECTIVES: The ADAURA trial demonstrated the benefit of adjuvant osimertinib among patients with resected, early-stage, epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC). To understand the potential population impact, it is critical to deduce the prevalence, management, and outcomes of this patient population in the real-world setting before use of adjuvant osimertinib....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.